## AMENDMENT

Please enter the following amendments to the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

## In the Claims:

- 1-3. (Cancelled)
- 4. (Currently Amended) A method of treating [[h]]Haemophilia A or [[h]]Haemophilia B, comprising administering by injection to a patient in need thereof a pharmaceutically an effective amount of a sterile pharmaceutical composition consisting essentially of coagulation [[f]]Factors VIII and IXa, wherein the presence of coagulation [[f]]Factor IXa [[allows]] reduces the concentration of coagulation [[f]]Factor VIII in the composition to be reduced in comparison to a composition which does not comprise [[a]] coagulation [[f]]Factor IXa, and wherein the sterile pharmaceutical composition is administered to said patient [[who]] does not present with anti-coagulation [[f]]Factor VIII antibodies.
  - (Cancelled)
- (Currently Amended) The method according to of claim 4, wherein the
  coagulation [[f]]Factor VIII and IXa reagents are produced using recombinant DNA technology
  is a von Willebrand Factor (vWF) B domain deleted rFVIII (recombinant Factor VIII).
- (Currently Amended) The method aeeerding to of claim 4, wherein the sterile pharmaceutical composition further comprises phospholipid.
- (Currently Amended) The method according to of claim 4, wherein the sterile
  pharmaceutical composition is formulated to provide coagulation [[f]]Factor VIII to a-subject
  said patient at a dosage of between 2 and 10 IU/kg.
  - 9-22. (Cancelled)